Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 15/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1729008 | 1.00 | F2R (0.71) | F2R | |
| SCHEMBL1729191 | 1.00 | F2R (0.71) | F2R | |
| SCHEMBL1732666 | 0.95 | F2R (0.71) | F2R | |
| SCHEMBL4264506 | 0.95 | F2R (0.71) | F2R | |
| SCHEMBL5487065 | 0.95 | F2R (0.73) | F2R | |
| SCHEMBL5490204 | 0.95 | F2R (0.73) | F2R | |
| SCHEMBL14449199 | 0.94 | F2R (0.79) | F2R | |
| Bromide SCHEMBL1730775 | 0.94 | F2R (0.80) | F2R | |
| Bromide SCHEMBL5488484 | 0.94 | F2R (0.80) | F2R | |
| SCHEMBL3980225 | 0.92 | F2R (0.77) | F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | claimed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | claimed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | claimed |
| EP-1614680-B1 | Process for preparing 2-iminopyrrolidine derivatives | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2290/4885 |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | F2R 1740/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2289/4885 |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | PTPRS, PTPMT1, PTPN1 | F2R 2712/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | F2R 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.